Axonics, Inc.: management transactions · United States · SEC (Form 4)

About Axonics, Inc.

Axonics, Inc. was a United States medical technology company headquartered in Irvine, California, in Southern California’s medtech corridor. It was listed on the Nasdaq under ticker AXNX and built its business around sacral neuromodulation, a minimally invasive therapy used to treat bladder and bowel dysfunction, including overactive bladder, fecal incontinence, and urinary retention. The company changed its name to Axonics, Inc. in March 2021, reflecting its evolution from Axonics Modulation Technologies into a broader commercial medtech platform focused on pelvic floor disorders. ([axonics.com](https://www.axonics.com/about-axonics/who-we-are/?utm_source=openai)) On the product side, Axonics developed a differentiated portfolio centered on long-lasting sacral neuromodulation systems. Its flagship offerings included the Axonics F15 recharge-free system, designed for extended battery life and broad MRI access, as well as other implantable neurostimulator and patient-control accessories intended to simplify therapy management. The company also commercialized Bulkamid, an injectable therapy for female stress urinary incontinence, giving Axonics exposure to a second adjacent urology / urogynecology market. This combination of neuromodulation and urinary incontinence therapies positioned the company in a niche category with meaningful clinical barriers, specialized physician adoption, and a recurring need for clinical education and patient support. ([axonics.com](https://www.axonics.com/hcp/axonics-system/recharge-free-snm?utm_source=openai)) Commercially, Axonics focused primarily on the United States, where it built its initial footprint through direct commercialization and physician engagement, while also expanding internationally through regulatory approvals and market access efforts. In its 2024 disclosures, management highlighted continued revenue growth driven by higher utilization among existing sacral neuromodulation customers and the onboarding of new accounts. That operating momentum mattered because Axonics competed in a market dominated by a small number of highly specialized medtech players, where product durability, patient convenience, MRI compatibility, and surgeon / urologist support can be decisive competitive factors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1603756/000160375624000061/axnx-03312024xex991.htm?utm_source=openai)) The most important recent event was the acquisition by Boston Scientific, completed on November 15, 2024. The transaction followed a merger agreement announced in January 2024 and subsequent regulatory review. For investors analyzing SEC Form 4 insider activity, the key contextual point is that Axonics ceased to be an independent public company after the closing of that deal; AXNX was no longer a standalone Nasdaq-listed equity once the acquisition was completed. In practical terms, any historical insider transaction analysis should therefore be interpreted in the context of a company that has already been taken private by a strategic acquirer. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1603756/000160375624000048/axnx-20240403.htm?utm_source=openai))